Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$RVMD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.06 down -133.59% YoY • Revolution Medicines is updating its full year 2026 GAAP operating expense guidance to a range of $2.1 to $2.2 billion, which includes estimated non-cash stock-based compensation expense of $270 to $290 million.

Price since post

Full Details

Advertisement|Remove ads.